STOCK TITAN

Cv Sciences - CVSI STOCK NEWS

Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.

CV Sciences, Inc. (CVSI) operates at the intersection of scientific innovation and natural wellness, developing hemp-derived supplements and plant-based nutrition solutions. This page serves as the definitive source for official company announcements, research breakthroughs, and operational developments.

Investors and industry stakeholders will find curated updates spanning regulatory milestones, product launches, and peer-reviewed studies validating CVSI's formulations. The archive includes earnings reports, manufacturing expansions, and clinical trial outcomes supporting their +PlusCBD and Cultured Foods brands.

All content undergoes rigorous verification to ensure alignment with financial disclosure standards and scientific accuracy. Users can efficiently track the company's progress in obtaining self-affirmed GRAS statuses, scaling global distribution networks, and advancing pet wellness innovations.

Bookmark this resource for real-time access to CV Sciences' advancements in cannabinoid research, nutraceutical safety protocols, and strategic partnerships within the consumer health sector. Regularly updated to reflect the company's evolving role in science-driven wellness solutions.

Rhea-AI Summary

CV Sciences (OTCQB: CVSI) announced its first quarter 2024 financial results.

The company generated $4.0 million in revenue, a 2.6% rise from the previous quarter but a 4% year-over-year decline. Its gross margin improved to 46.3% compared to 43.0% in Q1 2023 and 45.8% in Q4 2023. However, the cash balance dropped to $0.7 million from $1.3 million at the end of 2023. The company reported a $0.6 million operating loss, partly due to decreased B2B sales, although B2C sales rose by 3%. The acquisition of Elevated Softgels was highlighted as a strategic move for future growth. CV Sciences remains the top-selling hemp extract brand in natural product retail channels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

CV Sciences (OTCQB:CVSI) has acquired Elevated Softgels, a GMP-certified and FDA-registered manufacturer of encapsulated softgels and tinctures. Elevated Softgels' flexible production capabilities allow CV Sciences to in-source production of key products, potentially leading to significant cost savings. The acquisition involves a total consideration of up to $1,000,000, including a cash payment of $100,000, shares valued at $700,000, and up to $200,000 in performance-based earn-outs. Elevated Softgels, now a wholly-owned subsidiary, is expected to contribute to immediate growth and long-term shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

CV Sciences, Inc. will announce its first-quarter 2024 financial results on May 14, 2024. The company specializes in hemp extracts and natural products. The conference call with the investment community will take place at 7:00 a.m. Pacific Time on the same day. Interested investors can access the webcast on the Investor Relations section of the company's website, and a telephone replay will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
CV Sciences, Inc. reported financial results for fiscal 2023, showing a revenue of $16.0 million with a gross margin of 44.3%. Despite a slight decrease in sales, the company saw improvements in operating income and adjusted EBITDA. CV Sciences continued to expand its product offerings, launch new CBD products, receive patent approvals, and acquire Cultured FoodsTM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CV Sciences, Inc. launches +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews, backed by a safety study from the National Animal Supplement Council. The chews aim to improve pets' physical and emotional well-being with CBD and other natural ingredients, addressing joint pain and anxiety. The products are available nationwide and uphold strict quality standards, offering pet owners a safe and effective alternative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CV Sciences, Inc. (CVSI) will release financial results for the year and fourth quarter ended December 31, 2023, on March 28, 2024. The Company will hold a conference call with investors on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25%
Tags
Rhea-AI Summary
CV Sciences, Inc. (OTCQB: CVSI) has completed the acquisition of Cultured Foods, a leading manufacturer and distributor of alternative plant-based vegan foods, for a total consideration of up to $535,000. The acquisition creates opportunities for importation of specialty foods to the US and establishes a European base of operations for the sale and distribution of +PlusCBD products, contributing to the transition of CV Sciences into a more diverse global health and wellness company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CV Sciences, Inc. (OTCQB:CVSI) announced its financial results for the quarter ended September 30, 2023, with increased revenue to $4.1 million, recognized gross margin of 45.1%, and a cash balance of $1.6 million. The company also launched new products, executed an M&A strategy, and evaluated partnership opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CV Sciences, Inc. (OTCQB:CVSI) will release financial results for the third quarter ended September 30, 2023, before the stock market opens on Tuesday, November 14, 2023. The company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. Investors interested in participating in the live call can also dial (877) 300-8521 from the U.S. or international callers can dial (412) 317-6026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
CV Sciences launches +PlusCBD™ Reserve Collection Sleep Gummies to expand into the sleep aid market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Cv Sciences

OTC:CVSI

CVSI Rankings

CVSI Stock Data

5.71M
184.23M
0.02%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
San Diego